Manipal Health Enterprises Ltd (MANIPALHOS) Q2 FY27 Earnings Call: Best-Ever Quarter With 37% Revenue Growth, 440-500 Beds Expected in H2

Best-Ever Quarter: Volume-Led Growth With Margin Expansion

• Revenue of ~Rs.3,400 crore, up 37% YoY — CEO Dilip Jose described Q2 FY 2026-2027 as the company's best-ever quarter, with EBITDA of Rs.882 crore, up ~30% vs Q2 FY26.
• EBITDA margin of 27% ex-Sayadri — 26% at network level including Sayadri in Q2 FY 2026-2027.
• Inpatient volumes up ~35% and outpatient volumes up ~27% YoY — growth was volume-led in Q2 FY 2026-2027.
• Occupancy of 70% in Q2 FY27, up from 65% in Q1 FY27 — with average length of stay of 2.8 days; ARPOB ex-Sayadri was ~Rs.77,000/day (up over 8% YoY) and network ARPOB ~Rs.70,600/day.
• H1 FY27 revenue of Rs.6,490 crore, up ~38% — network EBITDA of Rs.1,631 crore (up 28%) and PAT of Rs.639 crore (~10% margin); H1 EBITDA margin was 26% ex-Sayadri and 25% at network level.
• Centers of excellence contributed 64.2% of H1 FY27 revenue — cardiology, oncology, neurology, gastroenterology, orthopedics and renal sciences, with oncology, neurology and orthopedics leading growth.

Greenfield Ramp, Gurugram Lease and Bed Addition Roadmap

• 440–500 beds expected in H2 FY 2026-2027 — including one greenfield and one brownfield project, plus ~100 beds from a brownfield project in FY 2027-2028, for roughly 550 beds across the two periods; Kinder Hospital adds ~100 beds on top, confirmed for FY 2027-2028.
• Major bed additions start from FY29 — when Mumbai comes on stream, per Group CFO Sameer Agarwal.
• Bangalore greenfields are identical at ~200–215 beds each — Yalahanka, Kanakapura and Electronic City each commission in two phases (150 beds phase one, 60 beds phase two); Kanakapura (just over one year old) posted 25% and Yelahanka (under one year old) 24% Q2 FY27 EBITDA margins.
• Mumbai (Juhu) is a 602-bed hospital and Raipur a 350-bed phase one — with capacity beyond 500 beds; Raipur greenfield comes on stream in Q4 FY 2026-2027. Mumbai and Raipur will be run as standalone hospitals with larger business-funnel footprints, and Mumbai is expected to take longer to break even than Bangalore, with short-term margin pressure accepted.
• 3.5-acre Gurugram lease registered — for a multi-specialty tertiary hospital with phase one planned at 500 beds; construction expected to complete in about 3 to 4 years.
• Electronic City reported a Q2 FY27 EBITDA loss of Rs.13 crore — operations began end-July 2026, September revenue more than doubled July's level, and a senior oncology team joins later in November 2026 with traction expected to build in FY 2026-2027.
• Karnataka cluster added 340 beds YoY — 150 beds each at Kanakapura and Yelahanka, with occupancy around 100 in each and both at 24–25% EBITDA margin in Q2 FY 2026-2027.

Government Scheme Transition Weighs on Volumes; Cash/TPA Offsets

• Government business volumes declined 17% on an H1 FY 2026-2027 basis — per Sameer Agarwal, while overall volumes remained positive; growth in cash and TPA more than offset the decline, described as the better-margin, good-payer segments.
• Dilip Jose attributed the East India volume decline to the state's transition of the Swasthya Sati scheme to Ayushman Bharat or its equivalent — Sameer Agarwal linked the fall to the Swasthya Sathi scheme coming down after the new state government took over, and said government business could rise again if the scheme comes back.
• Karthik Rajagopal called the East India government mix decline "a temporary phenomenon" — specific to that market, expecting government mix to return once the process is set; the company does not refuse treatment once empanelled but its sales, marketing and digital teams are focused on cash and TPA patients.
• A leading oncology team joined the Kolkata operations within the last 10 days — based at Takuria Hospital; the fire-affected Takuria annex has been refurbished and permitted to restart, forming the base of the oncology program; Dilip Jose hopes it will bring back volumes lost from the scheme transition.
• Cash and private insurance made up ~80% of payer mix in FY 2025-2026 — management is fairly comfortable with that range and does not expect it to change dramatically; government business is about 13–14% of payer mix.
• New Bangalore capacity (Kanakapura, Yelahanka, Electronic City) carries no government mix — purely cash and TPA; North India ramp-ups are expected to carry a government mix.

Sahyadri Margin March and Oncology Momentum

• Sahyadri EBITDA margin improved from 15.5% (FY 2025-2026) to 17.5% (Q1 FY27) to 19.5% (Q2 FY27) — a 200 bps QoQ improvement; Q2 revenue of Rs.375 crore (+13% QoQ) and EBITDA of Rs.73 crore (+26% QoQ); H1 FY27 revenue Rs.707 crore (+18%) and EBITDA Rs.131 crore (+24%).
• Management reiterated guidance of a 23–24% margin for Sahyadri over a 4 to 5 year period from acquisition — Dilip Jose said the company "could be pleasantly surprised" on timing but declined to give a specific margin for any quarter of FY 2027-2028; low-hanging fruit such as procurement and price efficiency could be rolled in early.
• Ex-Sahyadri Manipal business runs at a 27% margin (Q2 FY 2026-2027) — Dilip Jose said there is no reason Sahyadri could not reach that level, though management does not want to commit to it; the CFO noted a quarter may ramp faster while further investments may come later, and talent may be hired even at the cost of short-term targets.
• Oncology revenue grew 51% YoY in Q2 FY 2026-2027 — per analyst Aman Goel (IIFL Capital); it is ~12% of network revenue, with chemotherapy a fraction of that. Dilip Jose said oncology drug price capping is not expected to have an adverse impact in H2 FY 2026-2027, calling the exposure small and mitigable.
• A senior liver transplant team of 42 clinicians joined Sahyadri from 1 November 2026 — management expects hepatobiliary transplant volumes to "move up significantly"; digital revenue at Sahyadri rose to 11% of revenue with 300 doctor profiles created online.
• Sahyadri occupancy improved to 67% in Q2 FY27 but ARPOB declined sequentially from Rs.45,000 to Rs.44,100 — Karthik Rajagopal attributed this to a higher share of medical admissions from seasonal febrile illness, which lowered case mix by ~1%; average length of stay rose slightly. Insurance rate revisions continue in line with contractual inflation with no current headwinds; rebranding to Manipal Hospitals is still in process, and better insurance pricing may come only in the next negotiation cycle after the brand is established in Pune.

Digital Scale-Up and Tertiary-Care Concentration

• Digital revenue was ~23% of H1 FY27 revenue — with 34,000 e-pharmacy orders across 26 hospitals in 4 metros, 38,000 telehealth consultations (32,000 specialty) and 24,000 chatbot interactions in H1 FY 2026-2027.
• Company has "consciously stayed away" from diagnostics and pharmaceutical retail — Dilip Jose said it will stay focused on tertiary and quaternary care, where he described the company as exceptional; COO Karthik Rajagopal said the company is looking at out-of-hospital care, including home care and digital health delivered to patients' homes.
• Karnataka concentration reflects group origins — Manipal, Bangalore, Mangalore and Udupi, with the journey beyond Karnataka beginning only in the last 10 or 12 years; the group is now the largest private hospital network in eastern India and western India (including 9 hospitals in Pune), with 3 hospitals in Delhi and a large-capacity Gurgaon hospital signed up.
• Tier 2/3 presence is extensive and expansion continues — Mysore, Mangalore, Patiala, Rangapani and Siliguri; Dilip Jose cited affordability and aspiration for high-end healthcare, and said tier 2/3 does not imply government schemes as many such geographies have hardly any government scheme presence, with significant cash and TPA presence in Mysore and Patiala.

H2 Confidence, Occupancy Headroom and Guidance Stance

• Management declined to give FY 2027-2028 EBITDA guidance — responding to Goldman Sachs analyst Karan Vora on whether H2 FY 2026-2027 EBITDA would be around or slightly above H1 and an upside risk to FY28 guidance, Dilip Jose said the company does not yet give forward-looking numeric guidance and advised analysts to model FY 2026-2027 using the H1 and H2 trend.
• Management is "fairly confident" on H2 FY 2026-2027 — and said October 2026 "has also started well"; management looks forward to H2 FY27 "with optimism," citing growth levers from the last call that are "holding good."
• Occupancy rose from 65% (Q1 FY27) to 70.7% (Q2 FY27) without adding capex — the company is "fully loaded" on current capacity and expects ~80% aggregate occupancy; up to 80% occupancy can be reached without further capex, with new hospitals run on a modular model supporting 23–24% EBITDA margins.
• Finance costs rose sequentially in Q2 FY27 despite lower debt — debt was repaid only on 15 September, limiting the interest benefit to the last 15 days of the quarter; the full interest cost reduction will begin to show in Q3 FY 2026-2027.
• Only non-operational beds are at the new Kanakapura greenfield — operationalization depends on volumes in each market; nearly 3,800 licensed beds are management beds for MAHE and not part of operational capacity.